Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Clinicopathologic Assessment of Ocular Adnexal Lymphoproliferative Lesions at a Tertiary Eye Hospital in Iran

  • Published : 2016.08.01
⟨ Previous Next ⟩

Abstract

Background: The most common type of ocular lymphoma is non-Hodgkin lymphoma (NHL), categorized into two groups: indolent (slow growing) and aggressive (rapid growing). Differentiating benign reactive lymphoid hyperplasia (RLH) from malignant ocular adnexal lymphoma (OAL) is challenging. Histopathology, immunohistochemistry (IHC) and flow cytometry have been used as diagnostic tools in such cases. Materials and Methods: In this retrospective case series, from 2002 to 2013 at Farabi Eye Center, 110 patients with ocular lymphoproliferative disease were enrolled. Prevalence, anatomical locations, mean age at diagnosis and the final diagnosis of the disease with IHC were assessed. Comparison between previous pathologic diagnoses and results of IHC was made. Immunoglobulin light chains and B-cell and T-cell markers and other immuno-phenotyping markers including CD20, CD3, CD5, CD23, CD10, CYCLIND1 and BCL2 were evaluated to determine the most accurate diagnosis. The lymphomas were categorized based on revised European-American lymphoma (REAL) classification. Results: Mean age ${\pm}$ SD (years) of the patients was $55.6{\pm}19.3$ and 61% were male. Patients with follicular lymphoma, large B-cell lymphoma or chronic lymphocytic leukemia/small cell lymphoma (CLL/SLL) tended to be older. Nine patients with previous diagnoses of low grade B-cell lymphoma were re-evaluated by IHC and the new diagnoses were as follows: extranodal marginal zone lymphoma(EMZL) (n=1), SLL(n=1), mantle cell lymphoma (MCL) (n=3), reactive lymphoid hyperplasia RLH (n=2). Two cases were excluded due to poor blocks. Flow cytometry reports in these seven patients revealed SLL with positive CD5 and CD23, MCLwith positive CD5 and CyclinD1 and negative CD23, EMZL with negative CD5,CD23 and CD10. One RLH patient was negative for Kappa/Lambda and positive for CD3 and CD20 and the other was positive for all of the light chains, CD3 and CD20. Orbit (49.1%), conjunctiva (16.1%) and lacrimal glands (16.1%) were the most common sites of involvement. Conclusions: Accurate pathological classification of lesions is crucial to determine proper therapeutic approaches. This can be achieved through precise histologic and IHC analyses by expert pathologists.

Keywords

References

  1. Alkatan HM, Alaraj A, El-khani A, Al-Sheikh O (2013). Ocular adnexal lymphoproliferative disorders in an ophthalmic referral center in Saudi Arabia. Saudi J Ophthalmol, 27, 227-30. https://doi.org/10.1016/j.sjopt.2013.07.003
  2. Aronow ME (2015). Ocular Adnexal Lymphoma: Evidencebased Treatment Approach. Int Ophthalmol Clin, 55, 97-109. https://doi.org/10.1097/IIO.0000000000000049
  3. Aronow ME, Singh AD (2014). Ocular Adnexal Lymphoma: Clinical Features and Diagnostic Evaluation. In 'Ocular and Adnexal Lymphoma', Ed Singh AD, Springer-Verlag Berlin Heidelberg, 57-67
  4. Bhatia S, Paulino AC, Buatti JM, Mayr NA, Wen BC (2002). Curative radiotherapy for primary orbital lymphoma. Int J Radiat Oncol Biol Phys, 54, 818-23. https://doi.org/10.1016/S0360-3016(02)02966-8
  5. Bhurgri Y, Bhurgri H, Usman A, et al (2003). Epidemiology of ocular malignancies in Karachi. Asian Pac J Cancer Prev, 4, 352-7.
  6. Coupland SE, Krause L, Delecluse HJ, et al (1998). Lymphoproliferative lesions of the ocular adnexa: analysis of 112 cases. Ophthalmol, 105, 1430-41. https://doi.org/10.1016/S0161-6420(98)98024-1
  7. Domingo RE, Manganip LE, Castro RM (20015). Tumors of the eye and ocular adnexa at the Philippine Eye Research Institute: a 10-year review. Clin Ophthalmol, 9, 1239-47.
  8. Eckardt AM, Lemound J, Rana M, Gellrich NC (2013). Orbital lymphoma: diagnostic approach and treatment outcome. World J Surg Oncol, 11, 73. https://doi.org/10.1186/1477-7819-11-73
  9. Esmaeli B, Sniegowski M (2015). Orbital and Ocular Adnexal Lymphoma. In 'Orbital Tumors', Ed Karcioglu ZA, Springer, New York, 145-53.
  10. Ferry JA, Fung CY, Zukerberg L, et al (2007). Lymphoma of the ocular adnexa: a study of 353 cases. Am J Surg Pathol, 31, 170-84. https://doi.org/10.1097/01.pas.0000213350.49767.46
  11. Ghasemi M, Amoli FA, Gransar A (2003). A clinicopathologic study of orbital and ocular adnexal lymphoproliferative lesions with immunohistochemical staining of indeterminate cases. Acta Med Iran, 41, 11-4.
  12. Giridhar P, Mallick S, Bhasker S, et al (2015). Head and neck extra nodal NHL (HNENL)-treatment outcome and pattern of failure-a single institution experience. Asian Pac J Cancer Prev, 16, 6267-72. https://doi.org/10.7314/APJCP.2015.16.15.6267
  13. Gunduz K, Esmaeli B (2008). Diagnosis and management of malignant tumors of the eyelid, conjunctiva and orbit. Expert Rev Ophthalmol, 3, 63-75 https://doi.org/10.1586/17469899.3.1.63
  14. Harris NL, Jaffe ES, Stein H, et al (1994). A revised European- American classification of lymphoid neoplasms: a proposal from the international lymphoma study group. Blood, 84, 1361-92.
  15. Ioachim HL, Medeiros LJ (2009). Ioachim's lymph node pathology. Lippincott Williams & Wilkins, Wolters Kluwer, Philadelphia.
  16. Knowles DM, Jakobiec FA (1980). Orbital lymphoid neoplasms: A clinicopathologic study of 60 patients. Cancer, 46, 576-89. https://doi.org/10.1002/1097-0142(19800801)46:3<576::AID-CNCR2820460326>3.0.CO;2-D
  17. Laucirica R, Font RL (1996). Cytologic evaluation of lymphoproliferative lesions of the orbit/ocular adnexa: an analysis of 46 cases. Diagn Cytopathol, 15, 241-5. https://doi.org/10.1002/(SICI)1097-0339(199609)15:3<241::AID-DC13>3.0.CO;2-G
  18. Lee SJ, Jung JH, Choi HY (2013). Analysis of clinical features and prognostic factor analysis of orbital and adnexal lymphoma. J Korean Ophthalmol Soc, 54, 12-8. https://doi.org/10.3341/jkos.2013.54.1.12
  19. Li EY, Yuen HK, Cheuk W (2015). Lymphoproliferative Disease of the Orbit. Asia Pac J Ophthalmol, 4, 106-11. https://doi.org/10.1097/APO.0000000000000102
  20. Mannami T, Yoshino T, Oshima K, et al (2001). Clinical, histopathological, and immunogenetic analysis of ocular adnexal lymphoproliferative disorders: characterization of malt lymphoma and reactive lymphoid hyperplasia. Mod Pathol, 14, 641-9. https://doi.org/10.1038/modpathol.3880366
  21. Moslehi R, Coles FB, Schymura MJ (2011). Descriptive epidemiology of ophthalmic and ocular adnexal non- Hodgkin's lymphoma. Expert Rev Ophthalmol, 6, 175-80. https://doi.org/10.1586/eop.11.16
  22. Oh DE, Kim YD (2007). Lymphoproliferative diseases of the ocular adnexa in Korea. Arch Ophthalmol, 125, 1668-73. https://doi.org/10.1001/archopht.125.12.1668
  23. Othman IS (2009). Ophthalmic Pathology Interactive with Clinical Correlation. Kugler Publications, Amsterdam.
  24. Pfeffer MR, Rabin T, Tsvang L, et al (2004). Orbital lymphoma: Is it necessary to treat the entire orbit? Int J Radiat Oncol Biol Phys, 60, 527-30. https://doi.org/10.1016/j.ijrobp.2004.03.039
  25. Stacy RC, Jakobiec FA, Schoenfield L, Singh AD (2010). Unifocal and multifocal reactive lymphoid hyperplasia vs follicular lymphoma of the ocular adnexa. Am J Ophthalmol, 150, 412-26. https://doi.org/10.1016/j.ajo.2010.04.007
  26. Van der Gaag R, Koornneef L, Van Heerde P, et al (1984). Lymphoid proliferations in the orbit: malignant or benign? Br J Ophthalmol, 68, 892-900. https://doi.org/10.1136/bjo.68.12.892
  27. Zhu WW, Kang L, Gao YP, et al (2013). Expression level of valosin containing protein is associated with prognosis of primary orbital MALT lymphoma. Asian Pac J of Cancer Prev, 14, 6439-43. https://doi.org/10.7314/APJCP.2013.14.11.6439